Today's blog features a recent FDA Alert. FDA officials have recently issued a drug safety communication advising that buprenorphine and methadone should not be withheld from patients taking benzodiazepines or other central nervous system depressants. There needs to be precautions and a treatment plan in place when these medications are used in combination.Jennifer Barrett writes, "According to the safety announcement, though the combined use of these drugs may increase the risk of serious adverse effects, the benefits of treating opioid addiction can outweigh these risks. The announcement also said that, “excluding patients from medication-assisted treatment (MAT) or discharging patients from treatment because of use of benzodiazepines or CNS depressants is not likely to stop them from using these drugs together.”
To learn more, please read the full article HERE!
Performance Pharmacy Solutions (PPS) is a unique pharmacy benefit procurement platform developed by HORIZON Health Ventures to efficiently and effectively place, manage and oversee our self-funded client's pharmacy benefit management programs. The PPS platform provides turnkey solutions with proven market-leading PBM partners that offer, on average, 10-15% savings.
No comments:
Post a Comment